AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $85.87
- 52-wk high
- $95.49
- High
- $86.96
- 52-wk low
- $27.94
- Low
- $84.20
- Prev close
- $86.49
- Mkt cap
- $12.02B
- Volume
- 757.8K
- Fwd P/E
- 111.1x
- Beta
- 1.28
- P/S
- 18.0x
- P/B
- 26.2x
- Profit margin
- -47.8%
- Op margin
- -226.0%
- ROE
- -55.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 10.6% below what analysts expected.
Earnings per share
-$1.23 expected
What the street expects next
EPS expected
-$3.00 to -$0.35
Revenue expected
12 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $256.5M | $264.0M | $73.7M | $75.3M |
| Cost of what it sold | $6.4M | $6.4M | $6.4M | — |
| Gross profit | $256.5M | $264.0M | $73.7M | $75.3M |
| What it spent | ||||
| Research and development | $174.7M | $177.2M | $173.3M | $198.2M |
| Sales and admin | $37.2M | $45.5M | $41.2M | $46.6M |
| Total operating expenses | $212.4M | $223.2M | $215.0M | $245.3M |
| What was left | ||||
| Operating profit | $44.1M | $40.8M | -$141.3M | -$170.1M |
| Interest on debt | $21.7M | $22.5M | $23.8M | $24.6M |
| Profit before tax | $36.1M | $28.3M | -$137.6M | -$178.9M |
| Tax | $20.0M | $29.0K | $7.0K | $11.0K |
| Net profit | -$23.8M | $30.8M | -$132.7M | -$194.3M |
| EBITDA | $64.2M | $57.2M | -$107.4M | -$154.3M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
NeutralSep 6Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Leans bullishSep 4Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
NeutralSep 3Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Leans bullishSep 3Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
Leans bullishAug 31Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
BullishAug 31Arrowhead plans regulatory filing for plozasiran in sHTG By Investing.com
BullishAug 30Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
BullishAug 30
Macro
10 macro signals shaping ARWR right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results